Eleva

Executive Summary

Eleva is a clinical-stage biopharmaceutical company based in Munich, Germany, leveraging a proprietary moss-based platform to develop biologics for severe kidney disorders, dry age-related macular degeneration (AMD), complement-driven diseases, and enzyme replacement therapies. Founded in 2019, the company aims to unlock previously inaccessible biologics by utilizing moss as a production host, offering advantages in scalability, speed, and cost. Eleva is currently in Phase 1 clinical development, focusing on key therapeutic areas with high unmet need. Its platform has the potential to address complex protein targets that are challenging to produce using conventional mammalian cell systems. While specific pipeline details are limited, the company's innovative approach positions it as a notable player in the biologics space, particularly for conditions where current treatments are inadequate. The success of Eleva hinges on advancing its lead candidates through clinical trials and demonstrating the platform's versatility in producing functional biologics.

Upcoming Catalysts (preview)

• H2 2026Phase 1 data readout for lead kidney disease candidate60% success
• Q1 2027IND filing for dry AMD program50% success
• 2026Partnership or licensing deal for moss-based platform40% success